Which has higher valuation and earnings, SNN or IDXX?

IDEXX Laboratories has lower revenue, but higher earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.30B 1.83 $625M N/A N/A IDEXX Laboratories $4.55B 8.73 $1.06B $14.22 35.49

Does the media favor SNN or IDXX?

In the previous week, IDEXX Laboratories had 10 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 18 mentions for IDEXX Laboratories and 8 mentions for Smith & Nephew SNATS. IDEXX Laboratories' average media sentiment score of 1.13 beat Smith & Nephew SNATS's score of 0.06 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral IDEXX Laboratories 13 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, DXCM or SNN?

DexCom has higher earnings, but lower revenue than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.97B 6.31 $836.30M $2.53 32.82 Smith & Nephew SNATS $6.30B 1.83 $625M N/A N/A

Does the media prefer DXCM or SNN?

In the previous week, DexCom had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 14 mentions for DexCom and 8 mentions for Smith & Nephew SNATS. DexCom's average media sentiment score of 0.89 beat Smith & Nephew SNATS's score of 0.06 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, RMD or SNN?

ResMed has higher earnings, but lower revenue than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.65B 5.57 $1.52B $10.43 20.93 Smith & Nephew SNATS $6.30B 1.83 $625M N/A N/A

Does the media refer more to RMD or SNN?

In the previous week, ResMed had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 14 mentions for ResMed and 8 mentions for Smith & Nephew SNATS. ResMed's average media sentiment score of 1.11 beat Smith & Nephew SNATS's score of 0.06 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 12 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, SNN or GEHC?

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.30B 1.83 $625M N/A N/A GE HealthCare Technologies $21.27B 1.36 $2.08B $4.36 14.66

Does the media refer more to SNN or GEHC?

In the previous week, GE HealthCare Technologies had 9 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 17 mentions for GE HealthCare Technologies and 8 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 1.40 beat Smith & Nephew SNATS's score of 0.06 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral GE HealthCare Technologies 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SNN or PHG?

Smith & Nephew SNATS currently has a consensus price target of $31.91, suggesting a potential upside of 16.06%. Given Smith & Nephew SNATS's higher possible upside, research analysts clearly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew SNATS 1 Sell rating(s) 10 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Koninklijke Philips 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, SNN or PHG?

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.30B 1.83 $625M N/A N/A Koninklijke Philips $17.67B 1.37 $1.01B $1.36 18.10

Does the media favor SNN or PHG?

In the previous week, Smith & Nephew SNATS had 7 more articles in the media than Koninklijke Philips. MarketBeat recorded 8 mentions for Smith & Nephew SNATS and 1 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 1.00 beat Smith & Nephew SNATS's score of 0.06 indicating that Koninklijke Philips is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Koninklijke Philips 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Smith & Nephew SNATS (SNN) Competitors

$27.50 -0.13 (-0.45%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$27.48 -0.01 (-0.04%)

As of 09/11/2026 07:30 PM Eastern

Compare

SNN vs. IDXX, DXCM, RMD, GEHC, and PHG

Should you buy Smith & Nephew SNATS stock or one of its competitors? Smith & Nephew SNATS's main competitors and comparable companies include IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), GE HealthCare Technologies (GEHC), and Koninklijke Philips (PHG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Smith & Nephew SNATS compare to IDEXX Laboratories?

Smith & Nephew SNATS (NYSE:SNN) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

In the previous week, IDEXX Laboratories had 10 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 18 mentions for IDEXX Laboratories and 8 mentions for Smith & Nephew SNATS. IDEXX Laboratories' average media sentiment score of 1.13 beat Smith & Nephew SNATS's score of 0.06 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEXX Laboratories	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEXX Laboratories has lower revenue, but higher earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.30B	1.83	$625M	N/A	N/A
IDEXX Laboratories	$4.55B	8.73	$1.06B	$14.22	35.49

IDEXX Laboratories has a net margin of 25.03% compared to Smith & Nephew SNATS's net margin of 0.00%. IDEXX Laboratories' return on equity of 71.96% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
IDEXX Laboratories	25.03%	71.96%	33.60%

Smith & Nephew SNATS has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Smith & Nephew SNATS currently has a consensus price target of $31.91, suggesting a potential upside of 16.06%. IDEXX Laboratories has a consensus price target of $747.00, suggesting a potential upside of 48.01%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe IDEXX Laboratories is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

IDEXX Laboratories beats Smith & Nephew SNATS on 12 of the 14 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to DexCom?

DexCom (NASDAQ:DXCM) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

97.8% of DexCom shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

DexCom has a net margin of 20.12% compared to Smith & Nephew SNATS's net margin of 0.00%. DexCom's return on equity of 35.94% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Smith & Nephew SNATS	N/A	N/A	N/A

DexCom presently has a consensus price target of $88.71, indicating a potential upside of 6.84%. Smith & Nephew SNATS has a consensus price target of $31.91, indicating a potential upside of 16.06%. Given Smith & Nephew SNATS's higher probable upside, analysts plainly believe Smith & Nephew SNATS is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

DexCom has higher earnings, but lower revenue than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.97B	6.31	$836.30M	$2.53	32.82
Smith & Nephew SNATS	$6.30B	1.83	$625M	N/A	N/A

DexCom has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

In the previous week, DexCom had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 14 mentions for DexCom and 8 mentions for Smith & Nephew SNATS. DexCom's average media sentiment score of 0.89 beat Smith & Nephew SNATS's score of 0.06 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

DexCom beats Smith & Nephew SNATS on 12 of the 15 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to ResMed?

ResMed (NYSE:RMD) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.2%. Smith & Nephew SNATS pays an annual dividend of $0.59 per share and has a dividend yield of 2.1%. ResMed pays out 25.3% of its earnings in the form of a dividend. ResMed has raised its dividend for 13 consecutive years.

ResMed has a net margin of 26.94% compared to Smith & Nephew SNATS's net margin of 0.00%. ResMed's return on equity of 25.58% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	26.94%	25.58%	18.89%
Smith & Nephew SNATS	N/A	N/A	N/A

55.0% of ResMed shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.7% of ResMed shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ResMed has higher earnings, but lower revenue than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.65B	5.57	$1.52B	$10.43	20.93
Smith & Nephew SNATS	$6.30B	1.83	$625M	N/A	N/A

In the previous week, ResMed had 6 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 14 mentions for ResMed and 8 mentions for Smith & Nephew SNATS. ResMed's average media sentiment score of 1.11 beat Smith & Nephew SNATS's score of 0.06 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	12 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

ResMed presently has a consensus price target of $240.31, indicating a potential upside of 10.09%. Smith & Nephew SNATS has a consensus price target of $31.91, indicating a potential upside of 16.06%. Given Smith & Nephew SNATS's higher probable upside, analysts clearly believe Smith & Nephew SNATS is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ResMed has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Summary

ResMed beats Smith & Nephew SNATS on 12 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Smith & Nephew SNATS (NYSE:SNN) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Smith & Nephew SNATS has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Smith & Nephew SNATS currently has a consensus price target of $31.91, suggesting a potential upside of 16.06%. GE HealthCare Technologies has a consensus price target of $77.73, suggesting a potential upside of 21.58%. Given GE HealthCare Technologies' stronger consensus rating and higher possible upside, analysts clearly believe GE HealthCare Technologies is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.48

Smith & Nephew SNATS pays an annual dividend of $0.59 per share and has a dividend yield of 2.1%. GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. GE HealthCare Technologies pays out 3.2% of its earnings in the form of a dividend. GE HealthCare Technologies has increased its dividend for 1 consecutive years.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.30B	1.83	$625M	N/A	N/A
GE HealthCare Technologies	$21.27B	1.36	$2.08B	$4.36	14.66

GE HealthCare Technologies has a net margin of 9.33% compared to Smith & Nephew SNATS's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.12% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
GE HealthCare Technologies	9.33%	20.12%	5.74%

In the previous week, GE HealthCare Technologies had 9 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 17 mentions for GE HealthCare Technologies and 8 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 1.40 beat Smith & Nephew SNATS's score of 0.06 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
GE HealthCare Technologies	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GE HealthCare Technologies beats Smith & Nephew SNATS on 13 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Smith & Nephew SNATS (NYSE:SNN) and Koninklijke Philips (NYSE:PHG) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.30B	1.83	$625M	N/A	N/A
Koninklijke Philips	$17.67B	1.37	$1.01B	$1.36	18.10

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Smith & Nephew SNATS currently has a consensus price target of $31.91, suggesting a potential upside of 16.06%. Given Smith & Nephew SNATS's higher possible upside, research analysts clearly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Koninklijke Philips	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Koninklijke Philips has a net margin of 6.30% compared to Smith & Nephew SNATS's net margin of 0.00%. Koninklijke Philips' return on equity of 14.38% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Koninklijke Philips	6.30%	14.38%	5.96%

Smith & Nephew SNATS pays an annual dividend of $0.59 per share and has a dividend yield of 2.1%. Koninklijke Philips pays an annual dividend of $0.84 per share and has a dividend yield of 3.4%. Koninklijke Philips pays out 61.8% of its earnings in the form of a dividend.

In the previous week, Smith & Nephew SNATS had 7 more articles in the media than Koninklijke Philips. MarketBeat recorded 8 mentions for Smith & Nephew SNATS and 1 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 1.00 beat Smith & Nephew SNATS's score of 0.06 indicating that Koninklijke Philips is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Koninklijke Philips	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Summary

Koninklijke Philips beats Smith & Nephew SNATS on 8 of the 15 factors compared between the two stocks.

Get Smith & Nephew SNATS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNN vs. The Competition

Export

Metric	Smith & Nephew SNATS	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$11.60B	$5.38B	$7.14B	$23.17B
Dividend Yield	3.36%	1.79%	2.56%	3.56%
P/E Ratio	N/A	25.09	275.24	28.71
Price / Sales	1.83	82.90	656.02	94.44
Price / Cash	8.05	32.53	77.04	33.82
Price / Book	2.21	5.97	10.33	4.74
Net Income	$625M	$150.75M	$3.50B	$1.07B
7 Day Performance	-4.89%	-2.83%	-3.32%	-2.00%
1 Month Performance	-8.01%	-3.09%	-0.41%	-2.69%
1 Year Performance	-27.20%	9.34%	19.21%	10.45%

Smith & Nephew SNATS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNN Smith & Nephew SNATS	2.7159 of 5 stars	$27.50 -0.5%	$31.91 +16.1%	-28.6%	$11.60B	$6.30B	N/A	16,988	Analyst Downgrade
IDXX IDEXX Laboratories	4.1986 of 5 stars	$526.05 -1.7%	$747.00 +42.0%	-21.8%	$41.40B	$4.30B	36.95	11,000	News Coverage Positive News Insider Trade
DXCM DexCom	3.453 of 5 stars	$85.04 -3.3%	$88.71 +4.3%	+9.3%	$32.03B	$4.66B	33.55	11,000
RMD ResMed	4.1468 of 5 stars	$222.19 -2.7%	$240.31 +8.2%	-20.6%	$32.00B	$5.65B	21.27	11,370	Positive News Analyst Forecast Insider Trade
GEHC GE HealthCare Technologies	4.4661 of 5 stars	$67.28 -2.3%	$77.73 +15.5%	-18.0%	$30.37B	$20.63B	15.42	54,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SNN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Smith & Nephew SNATS (SNN) Competitors

SNN vs. IDXX, DXCM, RMD, GEHC, and PHG

How does Smith & Nephew SNATS compare to IDEXX Laboratories?

Summary

How does Smith & Nephew SNATS compare to DexCom?

Summary

How does Smith & Nephew SNATS compare to ResMed?

Summary

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Smith & Nephew SNATS (SNN) Competitors

SNN vs. IDXX, DXCM, RMD, GEHC, and PHG

How does Smith & Nephew SNATS compare to IDEXX Laboratories?

Does the media favor SNN or IDXX?

Which has higher valuation and earnings, SNN or IDXX?

Is SNN or IDXX more profitable?

Which has more volatility and risk, SNN or IDXX?

Do insiders and institutionals hold more shares of SNN or IDXX?

Do analysts prefer SNN or IDXX?

Summary

How does Smith & Nephew SNATS compare to DexCom?

Do institutionals and insiders have more ownership in DXCM or SNN?

Is DXCM or SNN more profitable?

Do analysts prefer DXCM or SNN?

Which has higher valuation & earnings, DXCM or SNN?

Which has more risk and volatility, DXCM or SNN?

Does the media prefer DXCM or SNN?

Summary

How does Smith & Nephew SNATS compare to ResMed?

Is RMD or SNN a better dividend stock?

Is RMD or SNN more profitable?

Do insiders and institutionals hold more shares of RMD or SNN?

Which has preferable earnings & valuation, RMD or SNN?

Does the media refer more to RMD or SNN?

Do analysts rate RMD or SNN?

Which has more volatility and risk, RMD or SNN?

Summary

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

Which has more volatility and risk, SNN or GEHC?

Do analysts prefer SNN or GEHC?

Is SNN or GEHC a better dividend stock?

Do insiders and institutionals hold more shares of SNN or GEHC?

Which has stronger valuation & earnings, SNN or GEHC?

Is SNN or GEHC more profitable?

Does the media refer more to SNN or GEHC?

Summary

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Which has better earnings & valuation, SNN or PHG?

Do institutionals & insiders believe in SNN or PHG?

Do analysts rate SNN or PHG?

Is SNN or PHG more profitable?

Is SNN or PHG a better dividend stock?

Does the media favor SNN or PHG?

Which has more volatility and risk, SNN or PHG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNN vs. The Competition

Smith & Nephew SNATS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools